BVAXF.US Biovaxys Technology Corp

Healthcare Biotechnology USA Stocks
0.0890 USD
Close of Nov 14, 2026
0.0102 0.2030
Market cap
USD 3.62M
P/E
-
P/B
8.86x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Apr 2025.

Is BVAXF.US undervalued?

Graham number

The Graham number of Biovaxys Technology Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biovaxys Technology Corp fundamental analysis

No fundamental analysis for Biovaxys Technology Corp yet.

Biovaxys Technology Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biovaxys Technology Corp

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory …

Full company profile